Differences

This shows you the differences between two versions of the page.

abstract:paper23 [2010/10/08 13:37]
bfvdonge
abstract:paper23 [2010/11/02 11:41] (current)
bfvdonge
Line 1: Line 1:
**Bert de Brock, Tommi Tervonen, Hans Hillege and Pieter de Graeff** **Bert de Brock, Tommi Tervonen, Hans Hillege and Pieter de Graeff**
-// Current Status and Future Perspectives of Drug Information Systems// +// {{:extendedabstract_23.pdf|Current Status and Future Perspectives of Drug Information Systems}}//
The information lifecycle of a drug starts already during the drug discovery phase and continues far into the future in prescription- and adverse-effect databases. In this paper, we describe the past literature and existing technology of Drug Information Systems (DIS). We develop a mapping of DIS to the phased drug lifecycle taking into account the system information contents. The mapping shows that currently there is a lack of DIS providing efficacy- and safety data in a suitable format. This lack severely hinders the possibility of physicians, researchers, as well as regulatory authorities and the pharmaceutical industry, to make quantitative analyses of efficacy and safety over a wide range of drugs. The information lifecycle of a drug starts already during the drug discovery phase and continues far into the future in prescription- and adverse-effect databases. In this paper, we describe the past literature and existing technology of Drug Information Systems (DIS). We develop a mapping of DIS to the phased drug lifecycle taking into account the system information contents. The mapping shows that currently there is a lack of DIS providing efficacy- and safety data in a suitable format. This lack severely hinders the possibility of physicians, researchers, as well as regulatory authorities and the pharmaceutical industry, to make quantitative analyses of efficacy and safety over a wide range of drugs.